Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Niemann-Pick disease is a rare genetic medical condition. There are four variants of this disease, categorized as type A, type B, type C, and type D. Niemann-Pick disease causes a variety of ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients. IntraBio's ...

Eugen Mengel, discussing a significant clinical trial's efficacy results in treating Niemann-Pick disease type C (NPC). MIPLYFFA is approved for use alongside miglustat in patients aged two and ...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation ...

Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...

Early onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and ...

One poster discussing efficacy results from a 12-month double-blind randomized trial of arimoclomol on the re-scored 4-domain Niemann-Pick disease type C (NPC) Clinical Severity Score (R4DNPCCSS ...

The confirmation comes after the World Health Organization (WHO) said last week that eight people had been killed by the disease in a remote part of Tanzania. The WHO chief Tedros Adhanom ...